Evidence map›Paper›PMID 38816982›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2024

Differential Inflammatory Responses in Adult and Pediatric COVID-19 Patients: Implications for Long-Term Consequences and Anti-Inflammatory Treatment.

Kacper Toczyłowski, Dawid Lewandowski, Diana Martonik, Anna Moniuszko-Malinowska, Ewelina Kruszewska, Anna Parfieniuk-Kowerda, Robert Flisiak, Artur Sulik

Abstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. COVID-19 in Children and Vitamin D.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kacper ToczyłowskiDepartment of Pediatric Infectious Diseases, Medical University of Białystok, Białystok, Poland.ORCID 0000-0003-0309-6987
Dawid LewandowskiDepartment of Pediatric Infectious Diseases, Medical University of Białystok, Białystok, Poland.
Diana MartonikDepartment of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok, Poland.ORCID 0000-0001-9183-602X
Anna Moniuszko-MalinowskaDepartment of Infectious Diseases and Neuroinfections, Medical University of Białystok, Białystok, Poland.ORCID 0000-0002-3994-8785
Ewelina KruszewskaDepartment of Infectious Diseases and Neuroinfections, Medical University of Białystok, Białystok, Poland.ORCID 0000-0002-6015-2351
Anna Parfieniuk-KowerdaDepartment of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok, Poland.ORCID 0000-0002-3815-3745
Robert FlisiakDepartment of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok, Poland.ORCID 0000-0003-3394-1635
Artur SulikDepartment of Pediatric Infectious Diseases, Medical University of Białystok, Białystok, Poland.ORCID 0000-0002-8391-4793

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND COVID-19 manifests with varying degrees of severity across different age groups; adults typically experience more severe symptoms than children. Matrix metalloproteinases (MMPs), known for their role in tissue remodeling and immune responses, may contribute to the pathophysiological disparities observed between these groups. We sought to delineate differences in serum MMP profiles between adult and pediatric COVID-19 patients, assess the influence of anti-inflammatory treatment on MMP levels, and examine potential implications for long-term consequences. MATERIAL AND METHODS Serum samples from adult and pediatric COVID-19 patients, alongside controls, were analyzed for MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-12, MMP-13, EMMPRIN, TNF-alpha, TIMP-1, TIMP-2, TIMP-3, and TIMP-4. A subset of adult patients received treatment with glucocorticoids, tocilizumab, and convalescent plasma, and MMP levels were compared with those of untreated patients. RESULTS Elevated levels of MMP-1, MMP-7, TIMP-1, and TIMP-2 were observed in adult and pediatric patients. Adult patients displayed higher concentrations of MMP-3, MMP-8, MMP-9, TNF-alpha, and TIMP-4 than children. Post-treatment reduction in MMP-1, MMP-8, MMP-9 levels was observed, with median decreases from 21% to 70%. MMP-3 and MMP-7 remained largely unchanged, and MMP-2 concentrations increased after treatment. Notably, anti-inflammatory treatment correlated with reduced post-treatment MMP levels, suggesting potential therapeutic benefit. CONCLUSIONS Distinctive inflammatory responses in COVID-19 were evident between adults and children. While certain MMPs exhibited post-treatment reduction, the persistence of elevated levels raises concerns about potential long-term consequences, including lung fibrosis. Our findings emphasize the need for personalized treatment strategies and further investigation into the dynamics of MMP regulation in COVID-19.

Indexed as

Anti-Inflammatory AgentsCOVID-19InflammationMatrix MetalloproteinasesSARS-CoV-2AdolescentAdultAgedChildChild, PreschoolCOVID-19 Drug TreatmentFemaleGlucocorticoidsHumansMaleMiddle AgedAnti-Inflammatory AgentsGlucocorticoidsMatrix Metalloproteinases

Identifiers

PMID38816982
PMCPMC11149468

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.